Sintilimab-Induced Myocarditis in a Patient with Gastric Cancer: A Case Report and Literature Review

Sintilimab-Induced Myocarditis in a Patient with Gastric Cancer: A Case Report and Literature Review

Immune checkpoint inhibitors (ICIs) have emerged as a powerful and efficacious therapeutic approach for many cancer patients. Sintilimab is a fully human IgG4 monoclonal antibody that binds with programmed cell death receptor-1 (PD-1) to block its interaction with ligands, thereby enhancing the anti...

Full description

Bibliographic Details
Main Authors:	Xin Liu, Ziyue Zeng, Jianlei Cao, Xianqing Li, Muheremu Muhetaer, Zhili Jin, Huanhuan Cai, Zhibing Lu
Format:	Article
Language:	English
Published:	MDPI AG 2023-10-01
Series:	Journal of Cardiovascular Development and Disease
Subjects:	gastric cancer immune checkpoint inhibitor programmed cell death receptor-1 sintilimab myocarditis
Online Access:	https://www.mdpi.com/2308-3425/10/10/422

Similar Items

Sintilimab-Induced Myocarditis Overlapping Myositis in a Patient With Metastatic Thymoma: A Case Report
by: Zi-xuan Yang, et al.
Published: (2021-12-01)

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
by: Le Zhang, et al.
Published: (2023-03-01)

A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma
by: Siming Zheng, et al.
Published: (2023-06-01)

Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review
by: Shujing Liang, et al.
Published: (2021-07-01)

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
by: Lingfang Tu, et al.
Published: (2021-12-01)

Refractory pruritus caused by sintilimab and its clinical management: A case report
by: Li Chen, et al.
Published: (2024-07-01)

Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review
by: Qihao Zhou, et al.
Published: (2024-09-01)

Immune myocarditis related to sintilimab treatment in a patient with advanced lung adenocarcinoma: A case report
by: Yunling Lin, et al.
Published: (2022-10-01)

Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report
by: Ming-xing Wang, et al.
Published: (2025-01-01)

Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review
by: Lei Wang, et al.
Published: (2024-04-01)

Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review
by: Zhang L, et al.
Published: (2023-02-01)

A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer
by: Yue Hu, et al.
Published: (2023-04-01)

Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report
by: Jiang Z, et al.
Published: (2023-11-01)

Case report: A rare case of sintilimab-induced gastric stenosis and literature review
by: Kunkun Song, et al.
Published: (2023-01-01)

Sintilimab, a PD-1 Inhibitor, Completely Reversed Rarely Refractory Hypofibrinogenemia in a Gastric Cancer Patient: A Case Report and Review of the Literature
by: Shuzhen Ma, et al.
Published: (2020-10-01)

Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report
by: Guo Hong, et al.
Published: (2023-10-01)

Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer:  A Case Report and Literature Review
by: Jingjing CAI, et al.
Published: (2023-09-01)

PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer
by: Yan Jia, et al.
Published: (2024-10-01)

Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment
by: Baohui Hong, et al.
Published: (2024-02-01)

Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress
by: Hongxiang Ji, et al.
Published: (2022-08-01)

Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis
by: Yunwei LIU, et al.
Published: (2021-09-01)

Immune checkpoint inhibitor myocarditis: a systematic case study
by: E. A. Kushnareva, et al.
Published: (2020-12-01)

Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature
by: Linlin Liu, et al.
Published: (2023-09-01)

Nursing of a patient with Sintilimab-induced autoimmune myocarditis (1例信迪利单抗治疗后出现免疫性心肌炎患者的护理)
by: HUANG Wenyi (黄雯薏), et al.
Published: (2023-04-01)

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
by: Nicolas Palaskas, et al.
Published: (2020-01-01)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
by: Huilai Lv, et al.
Published: (2022-04-01)

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
by: Jianzheng Wang, et al.
Published: (2022-06-01)

Establishment of a mouse myocarditis model induced by programmed death-1 inhibitor
by: CHEN Yifan, CHENG Leilei, SHEN Yihui, ZHANG Hui, WANG Xuejun, XU Yuchen, GE Junbo
Published: (2022-07-01)

Myocarditis associated with immune checkpoint inhibitors: Practical considerations in diagnosis and management
by: Muhammet Gürdoğan, et al.
Published: (2020-07-01)

A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer
by: Masaru Komatsu, et al.
Published: (2021-08-01)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
by: Dailong Li, et al.
Published: (2022-08-01)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
by: Huilai Lv, et al.
Published: (2023-01-01)

Efficacy and safety of oxaliplatin and capecitabine in combination with sintilimab as first-line treatment for HER2-negative advanced gastric cancer
by: ZHANG Xiaorui, SHAN Haixia, ZHU Zhengqiu
Published: (2025-01-01)

Drug therapy for myocarditis induced by immune checkpoint inhibitors
by: Yihao Wu, et al.
Published: (2023-05-01)

Case report: Undifferentiated sarcoma with multiple tumors involved in Lynch syndrome: Unexpected favorable outcome to sintilimab combined with chemotherapy
by: Jiaying Liu, et al.
Published: (2022-11-01)

Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report
by: Yi‐hui Li, et al.
Published: (2021-06-01)

Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib
by: Qian Xing, et al.
Published: (2022-09-01)

Immune checkpoint inhibitor‐induced myasthenia gravis, myocarditis, and myositis: A case report
by: Arjun Basnet, et al.
Published: (2024-06-01)

Acute retinal necrosis in a patient with cervical malignant tumor treated with sintilimab: a case report and literature review
by: Pei Wang, et al.
Published: (2024-01-01)